Equities

IPCA Laboratories Ltd

IPCALAB:NSI

IPCA Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,454.35
  • Today's Change4.60 / 0.32%
  • Shares traded597.20k
  • 1 Year change+56.89%
  • Beta0.4030
Data delayed at least 15 minutes, as of Sep 19 2024 11:26 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments8,45421,87413,701
Total Receivables, Net19,27111,88911,531
Total Inventory25,12017,73218,897
Prepaid expenses483312189
Other current assets, total2,06286254
Total current assets55,38951,89344,572
Property, plant & equipment, net46,63226,94625,026
Goodwill, net906381388
Intangibles, net1,4261,5911,672
Long term investments3,0363,0272,699
Note receivable - long term1,2101,5301,724
Other long term assets2,08575222
Total assets111,01386,26476,235
LIABILITIES
Accounts payable7,7615,2515,577
Accrued expenses949379527
Notes payable/short-term debt5,5926,6183,678
Current portion long-term debt/capital leases2,5881,506327
Other current liabilities, total6,6664,3054,550
Total current liabilities23,55618,05814,659
Total long term debt6,2036,6894,067
Total debt14,38414,8138,072
Deferred income tax3,1051,8921,644
Minority interest13,948733769
Other liabilities, total878473448
Total liabilities47,69127,84421,587
SHAREHOLDERS EQUITY
Common stock254254254
Additional paid-in capital965965965
Retained earnings (accumulated deficit)62,18957,21953,540
Treasury stock - common------
Unrealized gain (loss)(65)----
Other equity, total(21)(18)(110)
Total equity63,32258,42054,648
Total liabilities & shareholders' equity111,01386,26476,235
Total common shares outstanding254254254
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.